Curatis Holding AG (CHIX:CURNZ) Debt-to-EBITDA : -0.00 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Curatis Holding AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Curatis Holding AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF0.00 Mil. Curatis Holding AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF0.13 Mil. Curatis Holding AG's annualized EBITDA for the quarter that ended in Dec. 2023 was CHF-96.98 Mil. Curatis Holding AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Curatis Holding AG's Debt-to-EBITDA or its related term are showing as below:

CHIX:CURNz's Debt-to-EBITDA is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.68
* Ranked among companies with meaningful Debt-to-EBITDA only.

Curatis Holding AG Debt-to-EBITDA Historical Data

The historical data trend for Curatis Holding AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curatis Holding AG Debt-to-EBITDA Chart

Curatis Holding AG Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-EBITDA

-3.20

-0.08

Curatis Holding AG Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial			-1.25	-2.77	-0.04	-0.85	-

Competitive Comparison of Curatis Holding AG's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Curatis Holding AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curatis Holding AG's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Curatis Holding AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Curatis Holding AG's Debt-to-EBITDA falls into.

Curatis Holding AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Curatis Holding AG's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0.133)	/	-50.26
	=	-0.00

Curatis Holding AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0.133)	/	-96.982
	=	-0.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Curatis Holding AG (CHIX:CURNz) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Curatis Holding AG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Curatis Holding AG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Curatis Holding AG (CHIX:CURNZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curatis Holding AG (CHIX:CURNz) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

CURN:Switzerland

Address

Hochbergerstrasse 60C, Technologiepark Basel, Basel, CHE, 4057

Website

https://www.kinarus.com

Kinarus Therapeutics Holding AG In Liquidation Formerly Kinarus Therapeutics Holding AG is a clinical-stage pharmaceutical company focused on bringing novel treatments to patients suffering from viral, respiratory, and ophthalmic diseases. The company's therapeutic drug candidate, KIN001, consists of a clinical-stage p38 mitogen-activated protein kinase (p38 MAPK) inhibitor, in-licensed from Roche, combined with a marketed drug, together enabling an oral, long-term effective treatment for patients suffering from diseases with serious impact on quality of life.

Curatis Holding AG (CHIX:CURNZ) Headlines

No Headlines